Chart Review of Patients Undergoing Ketamine Infusions

Last updated: August 9, 2024
Sponsor: Brain and Cognition Discovery Foundation
Overall Status: Completed

Phase

N/A

Condition

Obsessive-compulsive Disorder

Bipolar Disorder

Panic Disorders

Treatment

Ketamine Hydrochloride

Clinical Study ID

NCT04209296
Pro00040593
  • Ages 18-65
  • All Genders

Study Summary

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Over the age of 18 years old. Patients over the age of 65 must receive additionalapproval to ensure safety.

  2. Diagnosed with either MDD, BD, PTSD or OCD by a healthcare provider.

  3. Experiencing an MDE as defined and operationalized in the DSM 5.0.

  4. Individuals who may have comorbid psychiatric conditions, but the comorbidpsychiatric condition can be neither the primary condition or the primary clinicalconcern.

  5. Individuals reporting suicidal ideation will be included, as suicidal ideation is asymptom of MDE.

  6. Individuals must have received at least 2 guideline concordant treatment trials withpharmacotherapeutic treatment options as suggested in the CANMAT MDD guidelines 2016, Florida Medicaid guidelines 2017, or the CANMAT ISBD guidelines for BD 2013.

  7. Individuals who have received ECT or other neuromodulatory treatments will beeligible for ketamine infusion.

Exclusion

Exclusion Criteria:

  1. Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorderin the past 3 months.

  2. Individuals who are experiencing psychotic symptoms as part of an MDE (moodcongruent/mood incongruent).

  3. Individuals who are unable to consent to the treatment.

  4. Individuals who are unable to adhere to the protocol in its totality (i.e., remainin the clinic post infusion for up to 2-3 hours for observation).

  5. Individuals who are unable to identify a person to assure their safe transport homefollowing ketamine infusion.

  6. Individuals with symptomatic traumatic brain injury.

  7. Uncontrolled medical disorders (i.e., uncontrolled and/or insufficiently treatedhypertension, allergies to ketamine and/or previous intolerability of ketamine).

  8. Pregnancy.

  9. Medical contraindications to ketamine.

  10. Patients that are over 275 lbs

Study Design

Total Participants: 891
Treatment Group(s): 1
Primary Treatment: Ketamine Hydrochloride
Phase:
Study Start date:
December 03, 2019
Estimated Completion Date:
September 14, 2023

Connect with a study center

  • Canadian Rapid Treatment Centre of Excellence

    Mississauga, Ontario L5C 4E7
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.